Denali Therapeutics - DNLI Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued twelve-month target prices for Denali Therapeutics' stock. Their DNLI share price forecasts range from $38.00 to $82.00. On average, they anticipate the company's stock price to reach $51.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts.

Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have increased by 14.0% and is now trading at $31.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DNLI earnings forecast.

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.23. The company earned $5.29 million during the quarter, compared to analyst estimates of $30.28 million. Denali Therapeutics had a negative net margin of 273.34% and a negative trailing twelve-month return on equity of 33.85%. Denali Therapeutics's revenue for the quarter was down 43.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) earnings per share.

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Denali Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.13%), New York State Common Retirement Fund (0.11%), ProShare Advisors LLC (0.02%), AIA Group Ltd (0.02%), Ironwood Investment Management LLC (0.01%) and Profund Advisors LLC (0.01%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNLI stock can currently be purchased for approximately $31.70.

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.31 billion and generates $48.66 million in revenue each year. The company earns $-290,580,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

The company employs 380 workers across the globe.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.